Skip to main content
OpenTrials
Completed

NCT Number: NCT01229007

Study of Biostate® in Children With Hemophilia A

The objective of this study is to assess the efficacy and safety of a Von Willebrand Factor/Factor VIII (VWF/FVIII), Biostate, and to investigate the pharmacokinetics of Biostate in children with haemophilia A.

Completed

Looking for future studies?

Notify Me

Key information

Age range

Up to 12 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 3

Primary location

Study site, Homyel, Belarus

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male subjects between 0 and <12 years of age.
  • Diagnosed with severe haemophilia A (FVIII:C <1%), and pre-treated for a minimum of 20 to 50 exposure days.
  • Have evidence of vaccination against hepatitis A and B (or presence of antibodies against hepatitis A and B due to either a previous infection or prior immunisation), as documented in the medical notes at enrolment.
  • The subject and/or legal guardian understand(s) the nature of the study and has/have given written informed consent to participate in the study and is/are willing to comply with the protocol.

Exclusion criteria

  • For all subjects at Day 1: Are actively bleeding.
  • Have received an infusion of any FVIII product, cryoprecipitate, whole blood, plasma or desmopressin acetate in the 4 days prior to their dosing within the PK component.
  • Have a known history of, or who are suspected of having FVIII inhibitors.
  • Have received aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) within 7 days of administration of the IMP.
  • Have an impaired liver function ie, bilirubin >1.5 x upper limit of normal (ULN) and/or aspartate/alanine aminotransferase (AST/ALT) >2.5 x ULN (referring to limits of the laboratory that performs the determination) at Screening.
  • Are human immunodeficiency virus [HIV]-1/-2 antibody positive with a viral load of >200/µL.
  • Suffer from an acute or chronic medical condition, other than haemophilia A, which may, in the opinion of the Investigator, affect the conduct of the study.
  • Suffering from von Willebrand disease (VWD) with von Willebrand factor: ristocetin cofactor (VWF:RCo) level <50 IU/dL at Screening.
  • Have a known or suspected hypersensitivity or previous evidence of severe side effects to a plasma-derived FVIII product or to human albumin.
  • Have participated in a clinical study or used an investigational compound in another study (eg, a new chemical entity not registered for clinical use) in the 3 months preceding the first day of IMP administration, or are planning to enter such a study during the study period.
  • Unwillingness and/or inability to comply with the study requirements.

Treatment and study plan

Biostate

Biological

1 dose of 50 IU FVIII/kg body weight of Biostate administered intravenously on Day 1 in the PK component, followed by the Efficacy component for continuation of Biostate therapy, as required for a minimum of 50 exposure days.

Primary outcomes

  1. Subjective assessment of Haemostatic efficacy

    Time frame: Over minimum of 50 exposure days

  2. Incremental recovery of FVIII

    Time frame: Samples taken prior and then 0.5, 4, 8, 24, and 48 h after the infusion on Day 1

  3. Half-life of FVIII

    Time frame: Samples taken prior and then 0.5, 4, 8, 24, and 48 h after the infusion on Day 1

  4. Area under the concentration curve (AUC) of FVIII

    Time frame: Samples taken prior and then 0.5, 4, 8, 24, and 48 h after the infusion on Day 1

  5. Mean residence time (MRT) of FVIII

    Time frame: Samples taken prior and then 0.5, 4, 8, 24, and 48 h after the infusion on Day 1

  6. Volume of distribution at steady state (Vss) of FVIII

    Time frame: Samples taken prior and then 0.5, 4, 8, 24, and 48 h after the infusion on Day 1

  7. Maximum Plasma Concentration (Cmax) of FVIII

    Time frame: Samples taken prior and then 0.5, 4, 8, 24, and 48 h after the infusion on Day 1

  8. Minimum Plasma Concentration (Cmin) of FVIII

    Time frame: Samples taken prior and then 0.5, 4, 8, 24, and 48 h after the infusion on Day 1

  9. Time the maximum concentration occurs (tmax) of FVIII

    Time frame: Samples taken prior and then 0.5, 4, 8, 24, and 48 h after the infusion on Day 1

  10. Total clearance of the drug from the body (CL=dose/AUC) of FVIII

    Time frame: Samples taken prior and then 0.5, 4, 8, 24, and 48 h after the infusion on Day 1

  11. Number of infusions per bleeding event

    Time frame: 1 day

  12. Number of infusions per month

    Time frame: 1 month

  13. Number of infusions per year

    Time frame: 1 year

  14. Dose (IU/kg) per bleeding event

    Time frame: 1 day

  15. Dose (IU/kg) per month

    Time frame: 1 month

  16. Dose (IU/kg) per year

    Time frame: 1 year

Secondary outcomes

  1. Frequency of adverse events (AEs)

    Time frame: 6 months

  2. Severity of AEs per subject

    Time frame: 6 months

  3. Severity of AEs per infusion

    Time frame: 6 months

  4. Relatedness of AEs per subject

    Time frame: 6 months

  5. Relatedness of AEs per infusion

    Time frame: 6 months

  6. Development of FVIII inhibitors

    Time frame: Samples taken at screening visit, on day 2, on months 1 and 3, and at final visit

Sponsors and collaborators

Lead sponsor

CSL Behring

Industry

Collaborators

  • Parexel

Registry information

Official study title

A Phase III, Open-Label, Multicentre Study to Evaluate Efficacy, Pharmacokinetics, and Safety of Biostate® in Paediatric Subjects With Haemophilia A

Important dates

Study start
2010
Primary completion
2014
Study completion
2014
First posted
Oct 27, 2010
Registry last updated
Aug 24, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.